Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRATUS: Abituzumab in SSc-ILD
NCT02745145Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- May 2016
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of abituzumab in systemic sclerosis-associated interstitial lung disease (SSc-ILD), sponsored by EMD Serono. Started May 2016; status: terminated.
02
Drugs
abituzumab
03
Conditions
systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT02745145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745145.